Literature DB >> 2647761

Fate of the patient with chronic leg ischaemia. A review article.

J Dormandy1, M Mahir, G Ascady, F Balsano, P De Leeuw, P Blombery, M G Bousser, D Clement, J Coffman, A Deutshinoff.   

Abstract

Much has been published on the surgical treatment of leg ischaemia but relatively little is known about the incidence of claudication and the fate of the majority of patients presenting with chronic leg ischaemia who never come to surgery. A review of the available literature suggests the following conclusions: (1) about 1.5% of men under 49 and 5% of men over 50 will develop symptoms of intermittent claudication. The incidence of asymptomatic arterial disease is much higher; (2) the incidence of claudication in women is only slightly less, but the local disease follows a more benign course; (3) compared to the general population of comparable age the mortality of men presenting with chronic leg ischaemia is two to three times higher after 5 years; (4) about 50% of deaths will be due to myocardial ischaemia, 15% to stroke and 10% to vascular disease in the abdomen. In only 25% will the principal cause of death be unconnected with the circulation; (5) there is virtually no reliable information available at the moment on the incidence of non-fatal myocardial infarction or stroke in these patients.

Entities:  

Mesh:

Year:  1989        PMID: 2647761

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  36 in total

Review 1.  Pharmacological treatment of patients with peripheral arterial disease.

Authors:  Chin K Kim; Carsten M Schmalfuss; Richard S Schofield; David S Sheps
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Current strategies in the diagnosis and management of lower extremity peripheral vascular disease.

Authors:  T J Wilt
Journal:  J Gen Intern Med       Date:  1992 Jan-Feb       Impact factor: 5.128

3.  Pentoxifylline in arterial disease of the legs.

Authors:  R Verhaeghe; M Verstraete
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Angiogenesis and vasculogenesis in treatment of cardiovascular disease.

Authors:  A Rivard; J M Isner
Journal:  Mol Med       Date:  1998-07       Impact factor: 6.354

5.  Prophylactic antiplatelet therapy in peripheral arterial disease.

Authors:  R Verhaeghe
Journal:  Drugs       Date:  1991       Impact factor: 9.546

6.  Coronary disease and stroke in patients with large-vessel peripheral arterial disease.

Authors:  M H Criqui; R D Langer; A Fronek; H S Feigelson
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 7.  Clinical Assessment of Peripheral Arterial Disease in the Office: What Do the Guidelines Say?

Authors:  Srini Tummala; Derek Scherbel
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

Review 8.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

9.  The ankle-brachial index as a predictor of survival in patients with peripheral vascular disease.

Authors:  M M McDermott; J Feinglass; R Slavensky; W H Pearce
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

10.  [Correlation between quantitative sensory testing and questionnaires on neuropathic pain for chronic ischemic pain in peripheral arterial disease].

Authors:  P M Lang; L J Rüger; T Abahji; U Hoffmann; A Crispin; D Irnich
Journal:  Schmerz       Date:  2009-06       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.